| Title |
A review of the cost effectiveness of bisphosphonates in the treatment of post-menopausal osteoporosis in Switzerland
|
|---|---|
| Published in |
Applied Health Economics and Health Policy, August 2012
|
| DOI | 10.2165/11592210-000000000-00000 |
| Pubmed ID | |
| Authors |
Kurt Lippuner, Richard F. Pollock, Jayne Smith-Palmer, Thomas Meury, William J. Valentine |
| Abstract |
The economic burden associated with osteoporosis is considerable. As such, cost-effectiveness analyses are important contributors to the diagnostic and therapeutic decision-making process. The aim of this study was to review the cost effectiveness of treating post-menopausal osteoporosis with bisphosphonates and identify the key factors that influence the cost effectiveness of such treatment in the Swiss setting. A systematic search of databases (MEDLINE, EMBASE and the Cochrane Library) was conducted to identify published literature on the cost effectiveness of bisphosphonates in post-menopausal osteoporosis in the Swiss setting. Outcomes were compared with similar studies in Western European countries. Three cost-effectiveness studies of bisphosphonates in this patient population were identified; all were from a healthcare payer perspective. Outcomes showed that, relative to no treatment, treatment with oral bisphosphonates was predicted to be cost saving for most women aged ≥70 years with osteoporosis or at least one risk factor for fracture, and cost effective for women aged ≥75 years without prior fracture when used as a component of a population-based screen-and-treat programme. Results were most sensitive to changes in fracture risk, cost of fractures, cost of treatment, nursing home admissions and adherence with treatment. Swiss results were generally comparable to those in other European settings. Assuming similar clinical efficacy, lowering treatment cost (through the use of price-reduced brand-name or generic drugs) and/or improving adherence should both contribute to further improving the cost effectiveness of bisphosphonates in women with post-menopausal osteoporosis. Published evidence indicates that bisphosphonates are estimated to be similarly cost effective or cost saving in most treatment scenarios of post-menopausal osteoporosis in Switzerland and in neighbouring European countries. |
X Demographics
The data shown below were collected from the profiles of 2 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 1 | 50% |
| United Kingdom | 1 | 50% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 2 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 58 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Spain | 3 | 5% |
| Denmark | 1 | 2% |
| Germany | 1 | 2% |
| Unknown | 53 | 91% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 11 | 19% |
| Student > Bachelor | 9 | 16% |
| Student > Ph. D. Student | 7 | 12% |
| Student > Master | 7 | 12% |
| Librarian | 4 | 7% |
| Other | 11 | 19% |
| Unknown | 9 | 16% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 26 | 45% |
| Nursing and Health Professions | 4 | 7% |
| Economics, Econometrics and Finance | 3 | 5% |
| Computer Science | 2 | 3% |
| Pharmacology, Toxicology and Pharmaceutical Science | 2 | 3% |
| Other | 8 | 14% |
| Unknown | 13 | 22% |
Attention Score in Context
This research output has an Altmetric Attention Score of 2. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 27 April 2020.
All research outputs
#15,169,949
of 25,374,917 outputs
Outputs from Applied Health Economics and Health Policy
#526
of 841 outputs
Outputs of similar age
#107,020
of 182,996 outputs
Outputs of similar age from Applied Health Economics and Health Policy
#78
of 82 outputs
Altmetric has tracked 25,374,917 research outputs across all sources so far. This one is in the 38th percentile – i.e., 38% of other outputs scored the same or lower than it.
So far Altmetric has tracked 841 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 9.3. This one is in the 35th percentile – i.e., 35% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 182,996 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 40th percentile – i.e., 40% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 82 others from the same source and published within six weeks on either side of this one. This one is in the 4th percentile – i.e., 4% of its contemporaries scored the same or lower than it.